Infant Bacterial Therapeutics AB (IBT B):企業の財務・戦略的SWOT分析

◆英語タイトル:Infant Bacterial Therapeutics AB (IBT B) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH2363473FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacillus reuteri, co-evolved human bacterial strain derived from human breast milk, used for the prevention of Necrotizing enterocolitis (NEC); and IBP-1016, a drug candidate used for the treatment of gastroschisis, a severe disease in infants. IBT develops pharmaceutical drug candidates for gastrointestinal neonatal condition that causes mucosal injury, necrosis, perforation in the intestinal tracts of infants and death. It operates through a network of neonatologists and research groups. IBT is headquartered in Stockholm, Sweden.

Infant Bacterial Therapeutics AB Key Recent Developments

Feb 05,2021: Infant Bacterial Therapeutics Interim Management Statement, January 1 – December 31, 2020
Nov 05,2020: Infant Bacterial Therapeutics interim management statement, January 1 – September 30, 2020
Aug 14,2020: Infant Bacterial Therapeutics interim management statement, January 1 – June 30, 2020
May 11,2020: Infant Bacterial Therapeutics interim management statement, January 1-March 31, 2020
Feb 11,2020: Infant Bacterial Therapeutics interim management statement, January 1 – December 31, 2019

This comprehensive SWOT profile of Infant Bacterial Therapeutics AB provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Infant Bacterial Therapeutics AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Infant Bacterial Therapeutics AB – Key Information
Infant Bacterial Therapeutics AB – Overview
Infant Bacterial Therapeutics AB – Key Employees
Infant Bacterial Therapeutics AB – Key Employee Biographies
Infant Bacterial Therapeutics AB – Key Operational Heads
Infant Bacterial Therapeutics AB – Major Products and Services
Infant Bacterial Therapeutics AB – History
Infant Bacterial Therapeutics AB – Company Statement
Infant Bacterial Therapeutics AB – Locations And Subsidiaries
Infant Bacterial Therapeutics AB
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Infant Bacterial Therapeutics AB – Business Description
Infant Bacterial Therapeutics AB – Corporate Strategy
Infant Bacterial Therapeutics AB – SWOT Analysis
SWOT Analysis – Overview
Infant Bacterial Therapeutics AB – Strengths
Infant Bacterial Therapeutics AB – Weaknesses
Infant Bacterial Therapeutics AB – Opportunities
Infant Bacterial Therapeutics AB – Threats
Infant Bacterial Therapeutics AB – Key Competitors

Section 3 – Company Financial Performance Charts

Infant Bacterial Therapeutics AB – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Infant Bacterial Therapeutics AB, Key Information
Infant Bacterial Therapeutics AB, Key Ratios
Infant Bacterial Therapeutics AB, Share Data
Infant Bacterial Therapeutics AB, Major Products and Services
Infant Bacterial Therapeutics AB, History
Infant Bacterial Therapeutics AB, Key Employees
Infant Bacterial Therapeutics AB, Key Employee Biographies
Infant Bacterial Therapeutics AB, Key Operational Heads
Infant Bacterial Therapeutics AB, Other Locations
Infant Bacterial Therapeutics AB, Subsidiaries
Infant Bacterial Therapeutics AB, Key Competitors
Infant Bacterial Therapeutics AB, SWOT Analysis
Infant Bacterial Therapeutics AB, Ratios based on current share price
Infant Bacterial Therapeutics AB, Annual Ratios
Infant Bacterial Therapeutics AB, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Infant Bacterial Therapeutics AB (IBT B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Horizon Pharma Plc (HZNP):製薬・医療:M&Aディール及び事業提携情報
    Summary Horizon Pharma plc (Horizon Pharma) is a pharmaceutical company which develops and commercializes medical products for the treatment of pain, arthritis and inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. The company’s marketed pro …
  • Eurofins Scientific SE (ERF):製薬・医療:M&Aディール及び事業提携情報
    Summary Eurofins Scientific SE (Eurofins) is a life sciences company, which provides a range of analytical testing services to clients in various industries. The company offers food and feed testing, biopharma services, pharma discovery services, genomic pharma services, pharma early development, ph …
  • Hon Hai Precision Industry Co Ltd (2317):企業の財務・戦略的SWOT分析
    Hon Hai Precision Industry Co Ltd (2317) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Kingfisher Plc:戦略・SWOT・企業財務分析
    Kingfisher Plc - Strategy, SWOT and Corporate Finance Report Summary Kingfisher Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Macronix International Co Ltd (2337):企業の財務・戦略的SWOT分析
    Macronix International Co Ltd (2337) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Taiwan Liposome Co Ltd (4152):企業の財務・戦略的SWOT分析
    Summary Taiwan Liposome Co Ltd (TLC) is a clinical-stage pharmaceutical company, which develops and commercializes novel nanomedicines based on drug delivery technology platform. The company’s pipeline products include TLC599, TLC590, TLC399 and TLC178. Its TLC 178 is used for the treatment of adult …
  • Herantis Pharma Plc (HRTIS):企業の財務・戦略的SWOT分析
    Summary Herantis Pharma Plc (Herantis Pharma) is a drug development company that offers regenerative medicine for neurodegenerative diseases. The company's pipeline products include CDNF for amyotrophic lateral sclerosis, CDNF for Parkinson’s disease and lymfactin for secondary lymphedema. Its lymfa …
  • Liberty Insurance Berhad:企業の戦略・SWOT・財務情報
    Liberty Insurance Berhad - Strategy, SWOT and Corporate Finance Report Summary Liberty Insurance Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • CMP Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CMP Pharma Inc (CMP Pharma), formerly Carolina Medical Products Company Inc is a specialty pharmaceutical company that develops and manufactures generic prescription, non-prescription and skin care products. The company’s prescription products include SPS suspension, isoniazid oral solution …
  • China Digital Culture (Group) Ltd (8175):企業の財務・戦略的SWOT分析
    China Digital Culture (Group) Ltd (8175) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Intermountain Rural Electric Association:企業の戦略的SWOT分析
    Intermountain Rural Electric Association - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Galectin Therapeutics Inc (GALT):企業の財務・戦略的SWOT分析
    Summary Galectin Therapeutics Inc (Galectin Therapeutics), formerly Pro-Pharmaceuticals Inc is a biotechnology company that discovers, develops and commercializes therapies for fibrotic disease and cancer. The company provides products such as GR-MD-02, GM-CT-01, and others. Its GR-MD-02 is a drug c …
  • Carvajal Empaques S.A.:企業の戦略・SWOT・財務情報
    Carvajal Empaques S.A. - Strategy, SWOT and Corporate Finance Report Summary Carvajal Empaques S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Greensmith Energy Management Systems LLC:電力:M&Aディール及び事業提携情報
    Summary Greensmith Energy Management Systems, LLC (Greensmith), a subsidiary of Wartsila Corporation, is a provider of energy storage management and services. The company specializes in software and control solutions to operate and manage Distributed Energy Storage Systems (DESS) for utility-scale, …
  • Regions Financial Corporation:戦略・SWOT・企業財務分析
    Regions Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary Regions Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • ABC arbitrage SA (ABCA):企業の財務・戦略的SWOT分析
    ABC arbitrage SA (ABCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Orkuveita Reykjavikur-エネルギー分野:企業M&A・提携分析
    Summary Orkuveita Reykjavikur (Orkuveita) is a public utility company that provides electricity and water. The company generates and supplies electricity. It harnesses hot water from geothermal fields and supplies it for heating applications. The company also supplies cold water from its groundwater …
  • SIGA Technologies Inc (SIGA):企業の財務・戦略的SWOT分析
    Summary Siga Technologies Inc (Siga) a subsidiary of MacAndrews and Forbes Holdings Inc, is a health security service provider. The company develops and commercialise solutions for serious unmet medical needs and bio threats. It offers antiviral drug to treat smallpox disease. Siga offers product su …
  • Lorain-Medina Rural Electric Cooperative Inc:企業の戦略的SWOT分析
    Lorain-Medina Rural Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Imperial College London-製薬・医療分野:企業M&A・提携分析
    Summary Imperial College London (Imperial) is a research university that offers educational services. The university provides undergraduate and postgraduate courses. It offers courses in the field of science and technology, agriculture, business, the humanities, and medicine. It conducts clinical tr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆